Hepatitis C virus infection triggers a tumor‐like glutamine metabolism

Pierre L. Lévy, Sarah Duponchel, Hannah Eischeid, Jennifer Molle, Maud Michelet, Gaëlle Diserens, Martina Vermathen, Peter Vermathen, Jean‐Francois Dufour, Hans‐Peter Dienes, Hans‐Michael Steffen, Margarete Odenthal, Fabien Zoulim, Birke Bartosch – 18 November 2016 – Chronic infection with hepatitis C virus (HCV) is one of the main causes of hepatocellular carcinoma. However, the molecular mechanisms linking the infection to cancer development remain poorly understood.

Lipid zonation and phospholipid remodeling in nonalcoholic fatty liver disease

Zoe Hall, Nicholas J. Bond, Tom Ashmore, Francis Sanders, Zsuzsanna Ament, Xinzhu Wang, Andrew J. Murray, Elena Bellafante, Sam Virtue, Antonio Vidal‐Puig, Michael Allison, Susan E. Davies, Albert Koulman, Michele Vacca, Julian L. Griffin – 18 November 2016 – Nonalcoholic fatty liver disease (NAFLD) can progress from simple steatosis (i.e., nonalcoholic fatty liver [NAFL]) to nonalcoholic steatohepatitis (NASH), cirrhosis, and cancer.

A new class of hepatitis B and D virus entry inhibitors, proanthocyanidin and its analogs, that directly act on the viral large surface proteins

Senko Tsukuda, Koichi Watashi, Taichi Hojima, Masanori Isogawa, Masashi Iwamoto, Katsumi Omagari, Ryosuke Suzuki, Hideki Aizaki, Soichi Kojima, Masaya Sugiyama, Akiko Saito, Yasuhito Tanaka, Masashi Mizokami, Camille Sureau, Takaji Wakita – 18 November 2016 – Introduction of direct‐acting antivirals against hepatitis C virus (HCV) has provided a revolutionary improvement in the treatment outcome.

Subscribe to